Akero Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Andrew Cheng
- Full Time Employees
- 69
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 601 Gateway Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Jun 20, 2019
- CIK
- 0001744659
- Website
- akerotx.com
- Similar Companies
- Business
- Akero Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases, primarily metabolic dysfunction-associated steatohepatitis (MASH), also known as nonalcoholic steatohepatitis (NASH). The company's main product candidate is efruxifermin (EFX), a novel fibroblast growth factor 21 (FGF21) analogue designed to treat MASH by targeting the core pathological processes of the disease. Akero continuously evaluates the potential expansion of EFX to treat other serious metabolic diseases and leverages its expertise in metabolic dysfunction and FGF21 biology to broaden its product pipeline. Akero operates primarily in the biotechnology and pharmaceutical industry segments, targeting patients with high unmet medical needs due to metabolic and liver diseases. The company conducts multiple ongoing clinical studies, including Phase 3 trials, to evaluate efruxifermin's efficacy and safety. Akero Therapeutics is headquartered in South San Francisco, California, and was founded in 2016. A major recent development for Akero Therapeutics is its definitive agreement to be acquired by Novo Nordisk A/S for up to $5.2 billion in cash, announced in October 2025. Under the terms of the deal, Akero shareholders will receive $54 per share in cash, with a contingent value right (CVR) adding up to an additional $6 per share upon regulatory approval of efruxifermin. This acquisition aligns with Novo Nordisk's strategic expansion beyond diabetes and obesity into MASH treatment, leveraging Akero's clinical-stage novel therapy to enhance its metabolic disease portfolio. Akero reported strong Phase 2b SYMMETRY trial results supporting efruxifermin's potential to reverse compensated cirrhosis in MASH patients, with ongoing progress in clinical development and significant cash reserves to fund operations into 2028. In summary, Akero Therapeutics specializes in the development of efruxifermin, a potentially best-in-class FGF21 analogue for metabolic liver diseases, notably MASH. Its acquisition by Novo Nordisk highlights the strategic value of its pipeline and positions the company for expanded development and commercialization under a leading global pharmaceutical entity.
Bourgeon Capital Management LLC Takes Position in Akero Therapeutics, Inc. $AKRO
Corient Private Wealth LLC Takes $3.93 Million Position in Akero Therapeutics, Inc. $AKRO
Alkeon Capital Management LLC Grows Stake in Akero Therapeutics, Inc. $AKRO
Novo Nordisk has completed its acquisition of Akero Therapeutics
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
My Top 3 Pharma Stocks
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)
Akero Therapeutics soars after Novo Nordisk set for $5.2B cash acquisition
Akero: Novartis Acquisition Puts Focus On Unprecedented MASH Data With EFX
Top Stock Movers Now: Delta Air Lines, PepsiCo, Akero Therapeutics, and More
Shareholder Alert: The Ademi Firm investigates whether Akero Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug
Akero Therapeutics Stock Surges on Novo Nordisk Buyout
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion
Novo Nordisk acquires Akero Therapeutics and its promising liver therapy for up to $5.2B